Society for Peritoneal Dialysis (JSPD), Keryx Biopharmaceuticals, Inc, Kidney Care UK, Kyowa Hakko Kirin Co., Ltd (since 1999 for Japan DOPPS), MEDICE Arzneimittel Pütter GmbH & Co KG, Otsuka America Pharmaceutical, Inc, Proteon Therapeutics, Inc, and The Association of German Nephrology Centres (Verband Deutsche Nierenzentren eV). Public funding and support is provided for specific DOPPS projects, ancillary studies, or affiliated research projects in the following countries: Australia-National diabetes, hypertension, or less advanced CKD. In conclusion, RAASi prescription patterns vary by country, and by demographic and clinical characteristics. RAASi appear to be underused, even among patients with strong class-specific recommendations.
Although the reasons for this variation could not be fully identified in this cross-sectional observation, our data indicate that the risk of hyperkalemia may contribute to the underuse of this class of agents in moderate to advanced CKD.
| INTRODUC TI ON
Given the high prevalence of diabetes, proteinuria, and congestive heart failure (CHF) in the chronic kidney disease (CKD) population, clinical practice guidelines support the prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) for most patients with CKD as a strategy to limit CKD progression and manage cardiac comorbidities. [1] [2] [3] The prescription pattern of RAASi in patients with CKD is still unknown, particularly in general nephrology practice in a "real-world setting."
Decreasing renal function and the associated interference with potassium (K) excretion is a major cause for potassium elevation. In clinical practice, however, the development of hyperkalemia is usually the result of a combination of factors superimposed on renal dysfunction, such as diabetes mellitus with high glucose levels or hyporeninemic hypoaldosteronism and advanced stages of heart failure with accompanying reductions in renal perfusion. 4 Additionally, serum potassium is influenced by the use of medications with hyperkalemic effects, such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), mineralocorticoid-receptor-antagonists (MRA), and medications that can lead a reduction in serum potassium level, such as diuretics, bicarbonate, and potassium binders. 
| ME THODS

| Study design and analytic cohort selection
We conducted a cross-sectional analysis of data from the CKDopps.
CKDopps is an ongoing international prospective cohort study of non-dialysis patients with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 . Participants were sequentially or randomly selected from national samples of nephrologist-run CKD clinics in Brazil, France, Germany, Japan, and the United States (US). The
CKDopps study design and protocol details have been published previously. 6 The ratio of enrolled patients with eGFR < 30 mL/ 
| Data and statistical analyses
Baseline cross-sectional data were used for the analyses.
Albuminuria was defined and classified into three categories according to Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines-normal or mildly increased (A1, <30 mg/g), (21) 131 (21) 133 (21) 143 (21) 142 (20) 142 (20) 139 (19) 137 (20) 138 (19) 136 (21) 138 (21) 137 ( 24. 7 (3.4) 25. 2 (3.4) 24. 8 (3.4) 24. 7 (3.8) 24. 9 (4.2) 24. 8 (3.9) 24. 7 (3.8) 24.1 (4.1) 24. 4 (3.9) Albuminuria or equivalent were used to estimate RAASi prevalence ratios (PR). All statistical analyses were conducted using SAS, version 9.4 (SAS Institute Inc).
| RE SULTS
After the application of inclusion and exclusion criteria, 5870 participants were included in the analysis (Figure 1 Figure 2 . Serum potassium levels were higher in more advanced stages of CKD. RAASi prescription was more common in Germany (80%) and France (77%) than Brazil (66%) and the United States (52%) ( Table 1 ). The prevalence of RAASi prescriptions, by country and by CKD stage, is shown in Patients prescribed RAASi were younger in all countries except Germany, had less advanced CKD, had greater prevalence of diabetes and hypertension, had higher serum potassium level, and more frequently were prescribed diuretics (Table 1) . According to the patient self-administered questionnaire, more than 50% of patients reported that the health care team did not recommend any change in potassium intake for the last 3 months prior to enrollment, despite the prescription of RAASi. The prevalence of RAASi prescription by indication for use is shown in Figure 4 . RAASi prescription was more frequent in patients with albuminuria in Brazil and France, but similar despite the presence of albuminuria in other countries ( Figure 4A ).
The prevalence of RAASi prescription was higher among those with diabetes than those without diabetes, despite the presence of albuminuria in France and the United States, but there was no noticeable difference in other countries ( Figure 4B ). Patients with CHF and albuminuria had higher prevalence of RAASi prescriptions in Brazil, but this was not observed in other countries ( Figure 4C ).
In the multivariable regression model (Table 2) 
| D ISCUSS I ON
Current guidelines support the prescription of RAASi for CKD patients, particularly those with diabetes, proteinuria, or heart failure.
The results of this multinational study indicate that RAASi are generally underused in advanced CKD, most strikingly in the United
States. RAASi prescriptions were more frequent with the presence of diabetes and hypertension comorbidities and less frequent with renal dysfunction, particularly at advanced CKD stages.
There were significant differences in RAASi prescription patterns across the different countries captured in this study, with a consistently higher RAASi prescription in France and Germany compared with the United States and Brazil; these differences were particularly visible in more advanced stages of CKD. These findings contrast with the analysis of the Ramipril Efficacy in Nephropathy (REIN) trial, which shows that the benefit of RAASi in reducing the progression of CKD is not dependent of the degree of kidney dysfunction at the moment when treatment is introduced. While hyperkalemia is only present in 2% of patients treated with RAASi due to hypertension with apparently normal kidney function, the incidence of hyperkalemia in patients with CKD is substantially higher. 10 In the Irbesartan Diabetic Nephropathy Trial (IDNT) of patients with type 2 diabetes and diabetic nephropathy, the incidence of hyperkalemia, as defined by a serum potassium >6.0 mmol/L, was 18.6%. 11 Previous studies identified CKD as an important risk factor for hyperkalemia. Interestingly, in patients with eGFR < 30 mL/min, the use of RAAS inhibitors was associated with an increased risk for hyperkalemia, and diuretics with an increased risk for hypokalemia. 12 In our study, hyperkalemia varied across different countries and particularly CKD stages.
As expected, mean serum potassium increases as GFR declines, as does the prevalence of hyperkalemia, as defined by serum potassium higher than 5.5 mEq/L. Hyperkalemia was more common in Brazil than the United States and Germany; several measures used to control hyperkalemia, such as prescription of diuretics, potassium-binding resins, and bicarbonate supplementation, as well as dietary advice varied across countries, were uncommon.
This finding contrasts with the importance of RAASi use and the high risk of hyperkalemia in this study's patient population.
Among medications studied, only the concomitant prescription of diuretics was associated with higher prevalence of RAASi prescription. Diuretics are commonly prescribed in the CKD population, particularly in moderate to advanced CKD for the treatment of hypertension and heart failure, but also as a strategy to control hyperkalemia. 13 The kaliuretic effects of these drugs may justify the higher prevalence of RAASi prescription in patients prescribed diuretics, since the increase of potassium excretion may reduce the potential of hyperkalemic events. 14, 15 and focused implementation science.
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The cross-sectional design of the analysis has some limitations in the interpretation of these analyses, since it does not allow for analysis of clinical decision-making, particularly related to events that motivated changes in prescription prior to the inclusion of patients in this study, for example, discontinuation, changes from dual to single therapy, and/or dose reduction that may occur in response to hyperkalemia. Further longitudinal investigation about the change in dose or change in prescription regimens in response to serum potassium levels is needed. Another limitation of the study is that the list of medications captured in the data analysis was limited due to the low prevalence of prescription, such as calcineurin inhibitors, sulfamethoxazole-trimethoprim, and non-steroidal anti-inflammatory agents.
RAASi prescription patterns in CKD vary by country, and by demographic and clinical characteristics. RAASi appear to be underused, especially in the United States, where only half were prescribed a RAASi, even among patients with strong class-specific recommendations, including albuminuria, diabetes, or heart failure. Higher potassium levels are associated with significantly higher RAASi prescription, before and after adjusting for covariates, an association which is likely to reflect the hyperkalemic effect of RAASi.
In conclusion, it is plausible that RAASi use may be less common in patients at higher risk of hyperkalemia; however, in cross-sectional analysis, this association may be confounded by: (a) RAASi discontinuation previous to the period of observation; and (b) introduction of anti-hyperkalemia measures (such as dose reduction, dietary advice, and potassium binder agents) not captured in the observation period. Therefore, prospective studies will need to address whether anti-hyperkalemia measures may allow greater RAASi use and potentially improve renal and cardiovascular outcomes in patients with moderate to advanced CKD.
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